IRESSA is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and: \uf0b7 that have certain types of abnormal epidermal growth factor receptor (EGFR) genes, and \uf0b7 who have not had previous treatment for cancer Your healthcare provider will perform a test to make sure that IRESSA is right for you. It is not known if IRESSA is safe and effective in people with NSCLC that have other types of EGFR genes. It is not known if IRESSA is safe and effective in children.<\/p>\n
Active ingredient: gefitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate<\/p>\n
If gefitinib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.<\/p>\n
Approval Date: 2015 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cgefitinib tablets\u201d based on the information you provide.<\/p>\n
\nProprietary Name: On Request
\nActive Ingredient(s): gefitinib tablets
\nDosage Forms And Strengths: Tablets: 250 mg
\nCompany: AstraZeneca
\nCurrent indications: non-small cell lung cancer (NSCLC)
\nMedicine Approved By: \u2013<\/strong>\u00a0European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n